RESEARCH

Systolic Blood Pressure Intervention Trial (SPRINT)
Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data 

Principal Investigator
Paul Drawz, MD

Program Manager
Nayanjot Kaur Rai, MPH, BDS
rai00041@umn.edu

Phase 2a Trial

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Principal Investigator 
Patrick Nachman, MD

Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu 

CLINICAL TRIAL

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Principal Investigator
Rasha El-Rifai, MD

Co-Investigator
Richard Spong, MD

Study Coordinator
Ghislaine Feussom, MPH
feuss001@umn.edu

CLINICAL TRIAL 

Phase 3

A Randomized, Controlled, Multi-Center, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus and Mycophenolate-Based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)

Principal Investigator
Erik Finger, MD, PhD

Co-Investigator
Rasha El-Rifai, MD

Study Coordinator
Marcia Brott
brott001@umn.edu

CLINICAL TRIAL 

Immunosuppression Reduction in Failed Allograft Guided by cfDNA

Principal Investigator
Adam Bregman, MD, MBA

Study Coordinator
Ghislaine Feussom, MPH
feuss001@umn.edu

CLINICAL TRIAL

Cf-DNA Assay During Treatment of Acute Rejection-Pilot Study

Principal Investigator
Arthur Matas, MD

Co-Investigators
Adam Bregman, MD, MBA

Study Coordinators
Marcia Brott
brott001@umn.edu

Alyssa Nelson, BS
nels9147@umn.edu

CLINICAL TRIAL

Phase 3 Trial

A Phase 3 open- label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Nattawat Klomjit, MD
Sahar Koubar, MBBS
Katie Pendleton, MD
Sami Safadi, MD

Study Coordinator

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

Phase 2a Trial

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

Phase 3 Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

Principal Investigator
Patrick H. Nachman, MD

Co-Investigators
Surabhi Thakar, MD

Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

Joy Bolea, RN, MS
jbolea@umn.edu

CLINICAL TRIAL

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy

Principal Investigator
Sahar Koubar, MBBS

Co-Investigators
Nattawat Klomjit, MD
Patrick H. Nachman, MD

CLINICAL TRIAL

Phase 2 Trial

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)

Principal Investigator
Patrick Nachman, MD

Co-Investigator
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinators

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

The Nephrotic Syndrome Study Network (NEPTUNE)

Principal Investigator
Patrick Nachman, MD

Co-Principal Investigator
Michelle Rheault, MD

Study Coordinators

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

Phase 2a Trial

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

Phase 3 Trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

Principal Investigator
Surabhi Thakar, MD

Co-Investigators
Patrick Nachman, MD
Katti Woerner, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

A Phase 2a Randomized Placebo-Controlled Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis (ITN091AI)

Principal Investigator
Patrick H. Nachman, MD

Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

Joy Bolea, RN, MS
jbolea@umn.edu

CLINICAL TRIAL

To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to clinical trials. Learn More

To provide patients with glomerular disease with expert, individualized care and access to clinical trials. Learn More